Director, Business Development, UK & Europe.

OXB; Oxford; On-site; GBP 70,000 - 90,000; Full time

Job summary

A leading CDMO in gene therapy located in Oxford is seeking a Director of Business Development to expand its services across the UK and Europe. The successful candidate will identify potential customers, lead contract negotiations, and collaborate with global teams to enhance strategic relationships. Ideal applicants will have a strong background in life sciences and proven expertise in business development. Competitive pay and a diverse work environment are offered.

Benefits

Highly competitive total reward packages

Wellbeing programmes

Development opportunities

Supportive colleagues

Diverse and inclusive environment

Qualifications

• Proven experience in life sciences or pharmaceutical companies.
• Significant experience in business development, preferably in B2B.
• Considerable knowledge in cell & gene therapy sector.

Responsibilities

• Identify and engage potential customers in gene therapy.
• Drive lead generation for the region.
• Lead contract negotiations with clients.

Skills

Business development

Sales & marketing

Strategic partnerships

Public speaking

Cross departmental collaboration

Education

Degree in Life Sciences or Business

Job description

Overview

We are at the centre of the rapidly growing cell and gene therapy sector. We deliver life-changing therapies to patients, and so can you.

We are currently recruiting for an experienced and dynamic Director of Business Development to join our Global Commercial Team. Located in the UK you will lead our efforts in expanding our viral vector CDMO services in the UK & Europe.

Our Commercial team works directly with prospective and current partners to provide strategic solutions enabling them to deliver life-changing gene therapy products to patients.

Responsibilities

• Identifying and engaging potential customers in the gene therapy and vaccine sectors and fostering long-term relationships that meet OXB’s business objectives
• Drive the Lead generation process for his region.
• Build and maintain strategic partnerships with key stakeholders, and clients, including biotech companies, research institutions, and industry leaders to expand awareness for OXB capabilities and drive long term growth.
• Collaborate with the Global Commercial Operations on the preparation of proposals to win new business as well as partnering with Commercial Program Management teams to manage active customer programs.
• Lead contract negotiations with clients, including Clinical and Commercial Supply, Services agreements and Licensing agreements.
• Cross collaboration with the wider Global Commercial & Marketing Teams to create compelling value propositions and promotional materials.
• Develop and share local market expertise, win/loss analysis, defining opportunities for differentiation, and updating competitive landscape in the CGT market.

Profile description

You will need:

• A degree education (Batchelor’s or Masters) within Life Sciences, business, PhD and/or MBA also welcome
• Proven experience in life sciences companies, pharmaceutical companies, CDMOs or related sectors with a preference for experience working in Cell and Gene therapies
• Significant experience in business development and/or sales & marketing roles for B2B business, preferably in the pharmaceutical services sector
• Considerable knowledge and understanding within the emerging cell & gene therapy sector ideally within a CDMO or similar business.
• Knowledge of the overall structure of biologics process development and GMP manufacturing projects in Pharma & Biotech.
• Commercial & Legal contract terms and used for customer contracts, including clinical and commercial supply agreements, process development agreements and license agreements.
• Strong communicator, public speaker & cross departmental collaborator both face to face and over digital platforms.
• An appreciation of working within a diverse international culture

About Us

OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.

What’s in it for you

• Highly competitive total reward packages
• Wellbeing programmes
• Development opportunities
• Welcoming, friendly, supportive colleagues
• A diverse and inclusive working environment
• Our values are: Responsible, Responsive, Resilient, Respect
• State of the art laboratory and manufacturing facilities

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you.

Collaborate. Contribute. Change lives

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.